Patents by Inventor Laising Yen
Laising Yen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250066796Abstract: Embodiments of the disclosure concern the use of expression constructs in which at least one polyA signal is embedded upstream of an expressible transcript, such as within a 5? UTR for the transcript, for example. In certain embodiments, the polyA signal is comprised within a ligand-binding aptamer, and the binding of the ligand to the aptamer, or lack thereof, dictates the outcome for the expressible transcript. In specific embodiments, absence of the ligand causes the expressed transcript having a polyA in its 5? UTR to be expressed but then degraded, whereas presence of the ligand causes inhibition of degradation upon expression of the expressible transcript. More than one ligand-binding aptamer may be present on the same expression construct.Type: ApplicationFiled: November 14, 2024Publication date: February 27, 2025Applicant: Baylor College of MedicineInventors: Laising Yen, Liming Luo, Pei-Wen Chao
-
Patent number: 12215323Abstract: Embodiments of the disclosure concern the use of expression constructs in which at least one polyA signal is embedded upstream of an expressible transcript, such as within a 5? UTR for the transcript, for example. In certain embodiments, the polyA signal is comprised within a ligand-binding aptamer, and the binding of the ligand to the aptamer, or lack thereof, dictates the outcome for the expressible transcript. In specific embodiments, absence of the ligand causes the expressed transcript having a polyA in its 5? UTR to be expressed but then degraded, whereas presence of the ligand causes inhibition of degradation upon expression of the expressible transcript. More than one ligand-binding aptamer may be present on the same expression construct.Type: GrantFiled: January 8, 2021Date of Patent: February 4, 2025Assignee: Baylor College of MedicineInventors: Laising Yen, Liming Luo, Pei-Wen Chao
-
Patent number: 12180473Abstract: Embodiments of the disclosure include methods and compositions in which two inter-chromosomal or intra-chromosomal genomic DNA regions are rearranged upon exposure of the genomic DNA to a chimeric RNA that produces fusion of the two regions. The chimeric RNA hybridizes to the two different parts of the genomic DNA and forms a DNA/RNA hybrid in a sequence-specific manner, thereby facilitating genomic rearrangement. In particular embodiments this mechanism is utilized to produce directed gene fusion in targeted genomic DNA regions.Type: GrantFiled: April 16, 2019Date of Patent: December 31, 2024Assignee: Baylor College of MedicineInventors: Laising Yen, Sachin Kumar Gupta, Jocelyn Duen-Ya Jea
-
Publication number: 20230332161Abstract: Embodiments of the disclosure include compositions and methods for generating RNA nanostructures, particularly in a cell. In particular embodiments, RNA subunits comprising at least one three-way junction and at least one kissing loop are configured such that multiple RNA subunits can polymerize into a specific structure. In particular embodiments, the RNA subunits are configured such that sequence of at least one kissing loop is complementary to sequence of another kissing loop, such as on another RNA subunit, and the summation of multiple RNA subunits having specific individual structures results in a combined polymerized structure of a defined shape. In specific embodiments, an RNA nanostructure generated from methods herein is utilized for an application, such as manufacturing or genetic modifications in a cell.Type: ApplicationFiled: March 1, 2023Publication date: October 19, 2023Inventor: Laising Yen
-
Patent number: 11597935Abstract: Embodiments of the disclosure include compositions and methods for generating RNA nanostructures, particularly in a cell. In particular embodiments, RNA subunits comprising at least one three-way junction and at least one kissing loop are configured such that multiple RNA subunits can polymerize into a specific structure. In particular embodiments, the RNA subunits are configured such that sequence of at least one kissing loop is complementary to sequence of another kissing loop, such as on another RNA subunit, and the summation of multiple RNA subunits having specific individual structures results in a combined polymerized structure of a defined shape. In specific embodiments, an RNA nanostructure generated from methods herein is utilized for an application, such as manufacturing or genetic modifications in a cell.Type: GrantFiled: November 10, 2017Date of Patent: March 7, 2023Assignee: Baylor College of MedicineInventor: Laising Yen
-
Publication number: 20220290147Abstract: Compositions and methods relating to regulation of gene expression are described. In some embodiments, the present disclosure provides compositions and methods for the regulation of gene expression using nucleic acid constructs. In some embodiments, the present disclosure recognizes the utility of alternative splicing in regulation of gene expression in a nucleic acid construct. In some embodiments, the present disclosure recognizes the utility of regulating gene expression utilizing ligand-binding aptamers.Type: ApplicationFiled: August 28, 2020Publication date: September 15, 2022Applicants: Baylor College of Medicine, Baylor College of MedicineInventors: Laising Yen, Liming Luo, Jocelyn Duen-Ya Jea
-
Publication number: 20210310003Abstract: Embodiments of the disclosure concern the use of expression constructs in which at least one polyA signal is embedded upstream of an expressible transcript, such as within a 5? UTR for the transcript, for example. In certain embodiments, the polyA signal is comprised within a ligand-binding aptamer, and the binding of the ligand to the aptamer, or lack thereof, dictates the outcome for the expressible transcript. In specific embodiments, absence of the ligand causes the expressed transcript having a polyA in its 5? UTR to be expressed but then degraded, whereas presence of the ligand causes inhibition of degradation upon expression of the expressible transcript. More than one ligand-binding aptamer may be present on the same expression construct.Type: ApplicationFiled: January 8, 2021Publication date: October 7, 2021Inventors: Laising Yen, Liming Luo, Pei-Wen Chao
-
Publication number: 20210238592Abstract: Embodiments of the disclosure include methods and compositions in which two inter-chromosomal or intra-chromosomal genomic DNA regions are rearranged upon exposure of the genomic DNA to a chimeric RNA that produces fusion of the two regions. The chimeric RNA hybridizes to the two different parts of the genomic DNA and forms a DNA/RNA hybrid in a sequence-specific manner, thereby facilitating genomic rearrangement. In particular embodiments this mechanism is utilized to produce directed gene fusion in targeted genomic DNA regions.Type: ApplicationFiled: April 16, 2019Publication date: August 5, 2021Inventors: Laising Yen, Sachin Kumar Gupta, Jocelyn Duen-Ya Jea
-
Publication number: 20200048716Abstract: MiniVectors and compositions containing MiniVectors that target ovarian cancer genes selected from FOXM1, AKT, CENPA, PLK1, CDC20, BIRC5, AURKB, CCNB1, CDKN3, BCAM-AKT2, CDKN2D-WDFY2, SLC25A6, CIP2A, CD133, ALDH1A1, CD44, SALL4, and/or PRDM16, alone or in any combination, are provided, along with uses in the treatment of ovarian cancer.Type: ApplicationFiled: November 5, 2018Publication date: February 13, 2020Inventors: E. Lynn Zechiedrich, Martin M. Matzuk, Laising Yen, Zhifeng Yu, Lirio Milenka Arevalo-Soliz, Daniel James Catanese, JR., Jonathan Marcus Fogg, Christopher Elbert Coker
-
Publication number: 20190330633Abstract: Embodiments of the disclosure include compositions and methods for generating RNA nanostructures, particularly in a cell. In particular embodiments, RNA subunits comprising at least one three-way junction and at least one kissing loop are configured such that multiple RNA subunits can polymerize into a specific structure. In particular embodiments, the RNA subunits are configured such that sequence of at least one kissing loop is complementary to sequence of another kissing loop, such as on another RNA subunit, and the summation of multiple RNA subunits having specific individual structures results in a combined polymerized structure of a defined shape. In specific embodiments, an RNA nanostructure generated from methods herein is utilized for an application, such as manufacturing or genetic modifications in a cell.Type: ApplicationFiled: November 10, 2017Publication date: October 31, 2019Inventor: Laising Yen
-
Patent number: 10233447Abstract: In certain embodiments, the disclosure relates to compositions and methods relating to a ribozyme-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to schistosome self-cleaving RNA mutant motifs.Type: GrantFiled: January 3, 2017Date of Patent: March 19, 2019Assignee: The Children's Medical Center CorporationInventors: Richard Mulligan, Laising Yen
-
Publication number: 20180327747Abstract: Embodiments of the disclosure concern the use of expression constructs in which at least one polyA signal is embedded upstream of an expressible transcript, such as within a 5? UTR for the transcript, for example. In certain embodiments, the polyA signal is comprised within a ligand-binding aptamer, and the binding of the ligand to the aptamer, or lack thereof, dictates the outcome for the expressible transcript. In specific embodiments, absence of the ligand causes the expressed transcript having a polyA in its 5? UTR to be expressed but then degraded, whereas presence of the ligand causes inhibition of degradation upon expression of the expressible transcript. More than one ligand-binding aptamer may be present on the same expression construct.Type: ApplicationFiled: November 11, 2016Publication date: November 15, 2018Inventors: Laising Yen, Liming Luo, Pei-Wen Chao
-
Publication number: 20170253872Abstract: In certain embodiments, the disclosure relates to compositions and methods relating to a ribozyme-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to schistosome self-cleaving RNA mutant motifs.Type: ApplicationFiled: January 3, 2017Publication date: September 7, 2017Applicant: The Children s Medical Center CorporationInventors: Richard Mulligan, Laising Yen
-
Publication number: 20160340743Abstract: Embodiments of the disclosure include methods and compositions associated with CDKN2D-WDFY2 chimeric RNA, the fusion gene that produces the chimeric RNA, and polypeptides produced from the chimeric RNA. In particular embodiments, the chimeric RNA is useful for methods of treatment, diagnosis, and/or prognosis as they relate to ovarian cancer, or therapy therefor, including at least high-grade serous carcinoma.Type: ApplicationFiled: February 10, 2015Publication date: November 24, 2016Inventors: Laising Yen, Kalpana Kannan
-
Publication number: 20150056174Abstract: In certain embodiments, the disclosure relates to compositions and methods relating to a ribozyme-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to schistosome self-cleaving RNA mutant motifs.Type: ApplicationFiled: May 14, 2012Publication date: February 26, 2015Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Richard Mulligan, Laising Yen
-
Publication number: 20110061120Abstract: In certain embodiments, the disclosure relates to compositions and methods relating to a ribozyme-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to schistosome self-cleaving RNA mutant motifs.Type: ApplicationFiled: March 1, 2010Publication date: March 10, 2011Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Richard Mulligan, Laising Yen
-
Publication number: 20050158741Abstract: In certain embodiments, the disclosure relates to compositions and methods relating to a ribozyme-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to schistosome self-cleaving RNA mutant motifs.Type: ApplicationFiled: November 15, 2004Publication date: July 21, 2005Applicant: Children's HospitalInventors: Richard Mulligan, Laising Yen